標題: Inter Partes Review: Patent Killer No More?
作者: Chen, Feng-Chi
Lee, Pin-Shen
科技法律學院
College of Law
公開日期: 1-七月-2019
摘要: Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community.
URI: http://dx.doi.org/10.1016/j.tibtech.2019.02.006
http://hdl.handle.net/11536/152312
ISSN: 0167-7799
DOI: 10.1016/j.tibtech.2019.02.006
期刊: TRENDS IN BIOTECHNOLOGY
Volume: 37
Issue: 7
起始頁: 680
結束頁: 683
顯示於類別:期刊論文